Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2CNS 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × sonidegib × Lymphoid × Clear all
NCT01826214 2016-08-30

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

Novartis

Phase 2 Completed
70 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡